Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: A retrospective review within the era of temozolomide

Journal of Neuro-Oncology

Volumn 113, Issue 2, 2013, Pages 305-311

  Shonka, Nicole A ^a   Theeler, Brett ^b   Cahill, Daniel ^c   Yung, Alfred ^d   Smith, Lynette ^a   Lei, Xiudong ^d   Gilbert, Mark R ^d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anaplastic astrocytoma; Chemotherapy; Radiation therapy; Treatment

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; RADIATION NECROSIS; RETROSPECTIVE STUDY; TUMOR BIOPSY; ADJUVANT CHEMOTHERAPY; ADOLESCENT; ANALOGS AND DERIVATIVES; ASTROCYTOMA; BRAIN NEOPLASMS; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84879092884     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1116-4     Document Type: Article

References (21)

1. CBTRUS statistical report (2011) Primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Central Brain Tumor Registry of the United States, Hinsdale
2. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359(9311):1011-1018
3. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Andersen AP, Elgen K (1981) Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 47(4):649-652
4. Medical Research Council Brain Tumor Working Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19(2):509-518
5. Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ (2008) Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer 44(9):1210-1216. doi: 10.1016/j.ejca.2007.12.005
6. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27(35):5874-5880. doi: 10.1200/JCO.2009.23.6497
7. NCCN Clinical Practice Guidelines. (2013) National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician-gls/pdf/cns.pdf. Accessed March 12 2013
8. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9(3):981-990
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996. doi: 10.1056/NEJMoa043330
10. Sidak Z (1967) Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 62:626-633
11. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52(6):997-1007
12. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D (1994) Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 44(8):1479-1483
13. Baehring JM, Marks PW (2012) Treatment-related myelodysplasia in patients with primary brain tumors. Neuro Oncol 14(5):529-540. doi: 10.1093/neuonc/ nos068
14. Levin VA, Ictech S, Hess KR (2007) Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer 7:106. doi: 10.1186/1471-2407-7-106
15. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113(2):405-410. doi: 10.1002/cncr.23562
16. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82(1):81-83. doi: 10.1007/s11060-006-9241-y
17. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707-718. doi: 10.1007/s00401-010-0781-z
18. Eyster EF, Nielsen SL, Sheline GE, Wilson CB (1974) Cerebral radiation necrosis simulating a brain tumor. Case report. J Neurosurg 40(2):267-271. doi: 10.3171/jns.1974.40.2.0267
19. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA (2000) Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 217(2):377-384
20. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2012) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. doi: 10.1200/JCO.2012.43.2229
21. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2012) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. doi: 10.1200/JCO.2012.43.2674